Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer

Inclusion Criteria

• •Histologically confirmed invasive breast carcinoma
• •* Tumor at least 1 cm by radiologic estimate or physical exam
• •* No disease limited to ductal carcinoma in situ only
• •Planning to undergo surgery at Memorial Sloan-Kettering Cancer Center
• •Hormone receptor status:
• •* Not specified
• •Female
• •Postmenopausal as defined by at least 1 of the following:
• •* No menstrual period within the past 12 months
• •* Prior bilateral oophorectomy
• •No known liver disease
• •No renal insufficiency
• •No congestive heart failure
• •No coronary artery disease
• •No history of documented peptic ulcer disease
• •No gastritis
• •No medical condition that would preclude definitive surgery
• •No allergy to NSAIDs or sulfa-containing drugs
• •No connective tissue diseases, including any of the following:
• •* Systemic lupus erythematosus
• •* Reynaud's disease
• •* Scleroderma
• •More than 3 months since prior chemotherapy
• •More than 2 weeks since prior hormone replacement therapy
• •More than 2 weeks since prior tamoxifen
• •More than 2 weeks since prior aromatase inhibitors
• •More than 2 weeks since prior raloxifene
• •More than 2 weeks since prior steroids
• •More than 1 week since prior nonsteroidal anti-inflammatory drugs (NSAIDs)
• •More than 1 week since prior cyclooxygenase (COX)-2 inhibitors
• •No concurrent warfarin
• •No concurrent thiazide or loop diuretics
• •No concurrent COX-2 inhibitors
• •No concurrent NSAIDs